Reduced cyclin D3 expression in erythroid cells protects against malaria
Summary
This study identifies a common Sardinian genetic variant (rs112233623-T) near the CCND3 gene that lowers cyclin D3 expression in erythroid precursors. The variant disrupts an enhancer binding site for the activating transcription factor SMAD3 and creates a site favoured by the repressive factor GATA1, reducing CCND3 transcription. Reduced cyclin D3 slows the G1→S transition during terminal erythropoiesis, producing fewer but larger red blood cells (higher MCV) and raising HbA2 (and modestly HbF) while lowering RBC count.
Functionally, red blood cells (RBCs) from carriers of the rs112233623-T allele show higher reactive oxygen species (ROS) and substantially impaired Plasmodium falciparum growth in vitro — effects comparable in direction to G6PD Mediterranean deficiency. Population-genetic analyses show signatures of positive selection for this allele in Sardinia, consistent with historic malaria pressure. The authors propose CCND3 inhibition as a potential adjunct antimalarial strategy, while noting cautions because cyclin D3 also has roles in immune cells.
Key Points
- rs112233623-T (CCND3 enhancer) reduces CCND3 mRNA and protein in erythroblasts by abolishing SMAD3 binding and increasing GATA1-mediated repression.
- Reduced cyclin D3 decreases erythroblast cell‑cycle progression, leading to fewer mitoses, larger erythrocytes (↑MCV), fewer RBCs (↓RBC count) and increased HbA2 (and modestly HbF).
- RBCs from rs112233623-T homozygotes show elevated ROS (H2O2) and markedly inhibit P. falciparum invasion/development in vitro across parasite strains.
- Population analyses in Sardinia indicate positive selection on the rs112233623-T haplotype (high FST, iHS and xp-EHH percentiles; CLUES-estimated selection coefficient), consistent with historic malaria as the selective pressure.
- The opposing enhancer variant rs9349205-A increases CCND3 expression and has opposite biological effects when not co-inherited with rs112233623-T; when co-inherited, the stronger rs112233623-T effect dominates.
- Therapeutic implication: transient CCND3 inhibition could be explored to reduce severe malaria risk (via increased ROS and altered erythropoiesis), but potential impacts on immune cells and long‑term safety require caution.
Why should I read this?
Short version: if you care about how human genetics and cell biology explain malaria resistance — and how that might point to new treatments — this paper is gold. It ties a clear molecular mechanism (enhancer change → less cyclin D3) to altered red‑cell physiology, to higher oxidative stress and, crucially, to real anti‑parasite effects in human cells. The Sardinia angle plus evidence for positive selection makes it a neat evolutionary story as well. Read it if you want the mechanistic detail and the experimental glue that links gene → cell → pathogen.
Context and relevance
This work connects classic ideas about malaria-driven selection of haemoglobin-related traits to a novel regulatory variant affecting cell‑cycle control in erythropoiesis. It broadens the roster of human adaptations that protect against malaria beyond haemoglobin and G6PD changes, showing a distinct mechanism based on erythroid cell‑cycle modulation and oxidative stress. The findings are relevant to researchers in human genetics, evolutionary biology, haematology and infectious disease, and they suggest a possible host‑directed therapeutic avenue complementary to parasite‑targeted drugs.
Author style
Punchy: the paper does the full circle — robust genetic signal, enhancer dissection, transcription factor binding changes, primary human erythroblast phenotypes, ROS/metabolite measures and direct parasite assays — and then ties it to population selection. If you work on malaria, red‑cell biology or host‑directed therapies, the experimental depth here means you should read the full text — the details matter for translating this into any clinical idea.